The machine learning technology platform developed by Gero will be used in a research partnership with Pfizer to identify possible treatment targets for fibrotic disorders utilising vast amounts of human-based data.
In their joint effort to find the genes and pathways that lead to fibrotic disorders, the businesses will draw on Pfizer’s experience and Gero’s technological platform. Pfizer would be in charge of additional preclinical and clinical development as well as possible therapeutic targets advancement.
Human data-driven drug discovery can reveal therapeutically significant targets for human (not rodent) diseases and avoid the “preclinical trap.” The irreversible aspect of human ageing, however, poses a challenge to genetically-based target identification against age-related disorders, according to Peter Fedichev, CEO of Gero. We can potentially find the most useful therapeutic targets by separating the irreversible impacts of ageing from the reversible disease phenotypes thanks to our technological platform.
Gero will be compensated up front and may also be eligible for discovery milestone payments if the project develops further.
According to Alex Kadet, CBO of Gero, “We are pleased to engage with Pfizer, one of the top biopharmaceutical firms in the world, to perhaps uncover targets against fibrotic disorders, which have a significant unmet need. “We think there is a chance to uncover high-value targets in this illness area by combining our platform technology with Pfizer’s considerable disease understanding.”
With the goal of slowing down human ageing itself, Gero is a biotechnology business in the preclinical stages of developing treatments against chronic diseases.
